A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic Renal Cell Carcinoma
Open Access
- 28 January 2010
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Journal of Translational Medicine
- Vol. 8 (1), 8
- https://doi.org/10.1186/1479-5876-8-8
Abstract
Due to the lack of specific tumor antigens, the majority of tested cancer vaccines for renal cell carcinoma (RCC) are based on tumor cell lysate. The identification of the von Hippel-Lindau (VHL) gene mutations in RCC patients provided the potential for developing a novel targeted vaccine for RCC. In this pilot study, we tested the feasibility of vaccinating advanced RCC patients with the corresponding mutant VHL peptides. Six patients with advanced RCC and mutated VHL genes were vaccinated with the relevant VHL peptides. Patients were injected with the peptide mixed with Montanide subcutaneously (SQ) every 4 weeks until disease progression or until the utilization of all available peptide stock. Four out of five evaluable patients (80%) generated specific immune responses against the corresponding mutant VHL peptides. The vaccine was well tolerated. No grade III or IV toxicities occurred. The median overall survival (OS) and median progression-free survival (PFS) were 30.5 and 6.5 months, respectively. The vaccine demonstrated safety and proved efficacy in generating specific immune response to the mutant VHL peptide. Despite the fact that the preparation of these custom-made vaccines is time consuming, the utilization of VHL as a vaccine target presents a promising approach because of the lack of other specific targets for RCC. Accordingly, developing mutant VHL peptides as vaccines for RCC warrants further investigation in larger trials. Trial registration: 98C0139Keywords
This publication has 50 references indexed in Scilit:
- T-regulatory cells in tumour-specific vaccination strategiesExpert Opinion on Biological Therapy, 2008
- Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinomaAmerican Journal of Health-System Pharmacy, 2008
- Re: Rising Incidence of Small Renal Masses: A Need to Reassess Treatment EffectJNCI Journal of the National Cancer Institute, 2007
- Identification of the Genes for Kidney Cancer: Opportunity for Disease-Specific Targeted TherapeuticsClinical Cancer Research, 2007
- Rising Incidence of Small Renal Masses: A Need to Reassess Treatment EffectJNCI Journal of the National Cancer Institute, 2006
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- Urological Oncology: Renal, Ureteral and Retroperitoneal TumorsJournal of Urology, 2002
- Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2002
- Unique tumor antigens redefined as mutant tumor-specific antigensSeminars in Immunology, 1996
- T-cell immunotherapy of cancerResearch in Immunology, 1991